Is adjuvant chemotherapy useful for soft-tissue sarcomas?
Mené sur 351 patients ayant subi une résection d'un sarcome des tissus mous à haut risque, cet essai randomisé évalue, du point de vue de la survie globale, l'efficacité d'une chimiothérapie adjuvante à base de doxorubicine, ifosfamide et lénograstime
For sarcomas, the story of adjuvant therapy can be described as “it was the best of times, it was the worst of times”. In the world of paediatric sarcomas, steady advances in adjuvant therapy have led to great increases in cure rates. Diseases such as rhabdomyosarcoma, Wilm's tumour, osteosarcoma, and Ewing's sarcoma have cure rates lower than 20% in the absence of chemotherapy. Today, with multimodality therapy, 60—90% of patients are cured. The success of our paediatric colleagues stems from various factors—ability to divide patients into appropriate histological and risk categories, high participation rates of patients on clinical trials, and sensitivity of paediatric sarcomas to systemic therapy...
The Lancet Oncology , commentaire en libre accès, 2011